Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged. The Health Care sector currently sits up 0.4% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Herbalife ( HLF), down 5.3%, Biogen Idec ( BIIB), down 1.6%, Celgene Corporation ( CELG), down 1.3%, Amgen ( AMGN), down 1.1% and Gilead ( GILD), down 1.0%. Top gainers within the sector include Agilent Technologies ( A), up 1.5%, Bristol-Myers Squibb Company ( BMY), up 1.2%, Novo Nordisk A/S ( NVO), up 1.2%, Allergan ( AGN), up 1.1% and Johnson & Johnson ( JNJ), up 0.8%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Illumina ( ILMN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Illumina is down $2.58 (-2.3%) to $107.76 on light volume. Thus far, 431,959 shares of Illumina exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $107.72-$109.87 after having opened the day at $109.13 as compared to the previous trading day's close of $110.34. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $14.0 billion and is part of the drugs industry. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Illumina Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.